Literature DB >> 21402479

Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.

Elisa Meacci1, Alfredo Cesario, Giacomo Cusumano, Filippo Lococo, Rolando D'Angelillo, Valentina Dall'armi, Stefano Margaritora, Pierluigi Granone.   

Abstract

OBJECTIVE: The surgical treatment of residual N2 disease following induction radio-chemotherapy (IT) for locally advanced cIIIA-N2 non-small-cell lung cancer (NSCLC) is still debated. The long-term results after resection in a pN2 series are at the focus of this study.
METHODS: From January 1992 to December 2008, 161 consecutive pathologically proven Stage IIIA-N2 NSCLC patients underwent IT. Among these, 40 pN2s were included in this retrospective analysis. The associations between the mortality and the disease-free status with potential risk factors were explored by means of the Kaplan-Meier and Cox regression analysis.
RESULTS: Mean age and male/female ratio were 58.7 ± 9.7 years and 36/4, respectively. Twelve patients (30%) showed a clinical partial response and 28 (70%) showed stable disease. There was one (3%) perioperative death and four (10%) major complications. In the total group, the 3- and 5-year survival rates were 24.2% and 19.3%, respectively. The Cox regression analysis suggested that the macroscopic pN2 status proved to be a negative prognostic factor (hazard ratio (HR)=2.8, confidence interval (CI) 95%: 1.1-7.3; p=0.04). The recurrence rate flattened at 30.8% at the 3rd year. Furthermore, the bilobectomy-pneumonectomy group had a risk of relapse 6.9 times higher than the lobectomy group (CI 95%: 2.5-18.8; p < 0.001).
CONCLUSIONS: The persistence of disease at the N2 level after IT and surgery for cIIIa-N2 NSCLC does not exclude favorable outcome after resection, in particular in those patients with minor residual disease.
Copyright © 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21402479     DOI: 10.1016/j.ejcts.2010.12.062

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Clinical value of nodal micrometastases in patients with non-small cell lung cancer: time for reconsideration?

Authors:  Angelo Carretta
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Surgical results and long-term follow-up of T(4)-non-small cell lung cancer invading the left atrium or the intrapericardial base of the pulmonary veins.

Authors:  Franco Stella; Andrea Dell'Amore; Guido Caroli; Giampiero Dolci; Nicola Cassanelli; Giulia Luciano; Fabio Davoli; Alessandro Bini
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-01-22

3.  Translocation of left inferior lobe pulmonary artery to the pulmonary artery trunk for central type non-small cell lung cancers.

Authors:  Yifeng Sun; Yang Yang; Yong Chen; Xufeng Pan; Yu Yang; Wen Gao; Heng Zhao; Jianxin Shi
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

4.  Transition from thoracotomy to uniportal video-assisted thoracic surgery in non-small cell lung cancer-the Oslo experience.

Authors:  Henrik Aamodt
Journal:  J Vis Surg       Date:  2016-06-29

5.  CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.

Authors:  Jiahui Si; Panpan Zhang; Dan Tian; Xing Wang; Yuanyuan Ma; Jianzhi Zhang; Lu Wang; Yue Yang
Journal:  World J Surg Oncol       Date:  2017-01-28       Impact factor: 2.754

Review 6.  Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.

Authors:  Branislav Jeremić; Francesc Casas; Pavol Dubinsky; Antonio Gomez-Caamano; Nikola Čihorić; Gregory Videtic; Ivan Igrutinovic
Journal:  Front Oncol       Date:  2018-02-20       Impact factor: 6.244

7.  A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.

Authors:  Anurag K Singh; Mark Hennon; Sung Jun Ma; Todd L Demmy; Anthony Picone; Elizabeth U Dexter; Chumy Nwogu; Kristopher Attwood; Wei Tan; Gregory M Hermann; Simon Fung-Kee-Fung; Harish K Malhotra; Sai Yendamuri; Jorge A Gomez-Suescun
Journal:  BMC Cancer       Date:  2018-11-29       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.